The FDA's 'Study May Proceed' notification is a critical regulatory milestone that allows Alzamend Neuro to advance its clinical trial for AL001. This news is likely to be viewed positively by investors as it demonstrates progress in the company's drug development pipeline, which could lead to future revenue streams if the drug is successful. The direct mention of ALZN and the specificity of the drug candidate and trial phase make this news highly relevant and important to the company. The confidence score reflects the typical market response to positive regulatory updates, although the actual impact on the stock price can be influenced by broader market conditions and investor sentiment.